➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Mallinckrodt
Baxter
Boehringer Ingelheim
McKinsey

Last Updated: February 27, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for AZD5363

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for AZD5363?

AZD5363 is an investigational drug.

There have been 27 clinical trials for AZD5363. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2014.

The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are AstraZeneca, Cancer Research UK, and Royal Marsden NHS Foundation Trust.

There are fifteen US patents protecting this investigational drug and one hundred and eighty international patents.

Recent Clinical Trials for AZD5363
TitleSponsorPhase
Capivasertib China PK StudyAstraZenecaPhase 1
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerDaiichi Sankyo Company, LimitedPhase 1
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerAstraZenecaPhase 1

See all AZD5363 clinical trials

Clinical Trial Summary for AZD5363

Top disease conditions for AZD5363
Top clinical trial sponsors for AZD5363

See all AZD5363 clinical trials

US Patents for AZD5363

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD5363   Start Trial Polymeric nanoparticles and methods of making and using same Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY)   Start Trial
AZD5363   Start Trial Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD5363   Start Trial Protein kinase B inhibitors AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD5363   Start Trial Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof RACE ONCOLOGY LTD. (Melbourne, AU)   Start Trial
AZD5363   Start Trial Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor AstraZeneca AB (Sodertaje, SE)   Start Trial
AZD5363   Start Trial Chemical compounds AstraZeneca AB (Sodertalje, SE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD5363

Drugname Country Document Number Estimated Expiration Related US Patent
AZD5363 European Patent Office EP3119395 2034-03-17   Start Trial
AZD5363 World Intellectual Property Organization (WIPO) WO2015142605 2034-03-17   Start Trial
AZD5363 Australia AU2013204533 2032-04-17   Start Trial
AZD5363 Canada CA2869936 2032-04-17   Start Trial
AZD5363 China CN104203953 2032-04-17   Start Trial
AZD5363 European Patent Office EP2847194 2032-04-17   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Mallinckrodt
Baxter
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.